Open AccessHyaluronic acid derivative-modified nano-structured lipid carrier for cancer targeting and therapy
Author(s) -
Xiao Liu,
Hai Lü,
Sulan Wang,
Jingwen Liu
Publication year - 2020
Publication title -
journal of zhejiang university. science b
Language(s) - English
Resource type - Journals
eISSN - 1862-1783
pISSN - 1673-1581
DOI - 10.1631/jzus.b1900624
Subject(s) - in vivo , hyaluronic acid , paclitaxel , chemistry , internalization , cd44 , cytotoxicity , endocytosis , solid lipid nanoparticle , nanoparticle , drug carrier , biophysics , in vitro , biochemistry , materials science , nanotechnology , drug delivery , receptor , cancer , biology , organic chemistry , genetics , microbiology and biotechnology
To reduce the problems of poor solubility, high in vivo dosage requirement, and weak targeting ability of paclitaxel (PTX), a hyaluronic acid-octadecylamine (HA-ODA)-modified nano-structured lipid carrier (HA-NLC) was constructed. HA-ODA conjugates were synthesized by an amide reaction between HA and ODA. The hydrophobic chain of HA-ODA can be embedded in the lipid core of the NLC to obtain HA-NLC. The HA-NLC displayed strong internalization in cluster determinant 44 (CD44) highly expressed MCF-7 cells, and endocytosis mediated by the CD44 receptor was involved. The HA-NLC had an encapsulation efficiency of PTX of 72.0%. The cytotoxicity of the PTX-loaded nanoparticle HA-NLC/PTX in MCF-7 cells was much stronger than that of the commercial preparation Taxol®. In vivo, the HA-NLC exhibited strong tumor targeting ability. The distribution of the NLCs to the liver and spleen was reduced after HA modification, while more nanoparticles were aggregated to the tumor site. Our results suggest that HA-NLC has excellent properties as a nano drug carrier and potential for in vivo targeting.